Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Overview | 6 | 1 |
| Therapeutics Development | 7 | 4 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Products under Development by Stage of Development | 7 | 1 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Products under Development by Therapy Area | 8 | 1 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Products under Development by Indication | 9 | 2 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Pipeline Products Glance | 11 | 2 |
| Late Stage Products | 11 | 1 |
| Early Stage Products | 12 | 1 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Products under Development by Companies | 13 | 3 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Therapeutics Assessment | 16 | 4 |
| Assessment by Monotherapy/Combination Products | 16 | 1 |
| Assessment by Mechanism of Action | 17 | 1 |
| Assessment by Route of Administration | 18 | 1 |
| Assessment by Molecule Type | 19 | 1 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Companies Involved in Therapeutics Development | 20 | 4 |
| Arrien Pharmaceuticals, LLC | 20 | 1 |
| Daiichi Sankyo Company, Limited | 21 | 1 |
| Ignyta, Inc. | 22 | 1 |
| Pfizer Inc. | 23 | 1 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Drug Profiles | 24 | 18 |
| ARN-5032 Drug Profile | 24 | 1 |
| crizotinib Drug Profile | 25 | 7 |
| DS-6051 Drug Profile | 32 | 1 |
| entrectinib Drug Profile | 33 | 6 |
| lorlatinib Drug Profile | 39 | 2 |
| TPX-0005 Drug Profile | 41 | 1 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Dormant Projects | 42 | 1 |
| Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) Featured News &Press Releases | 43 | 15 |
| Jul 21, 2016: CHMP adopts extension to existing therapeutic indication for Xalkori | 43 | 1 |
| Jun 14, 2016: AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer | 43 | 1 |
| Jun 06, 2016: Pfizer Presents Promising Data From Next Generation ALK/ROS1 Inhibitor In Advanced Non-Small Cell Lung Cancer | 44 | 1 |
| Jun 03, 2016: Crizotinib Demonstrates Clinical Benefit in Phase II Study of East Asian Patients with ROS1-Positive Non-Small Cell Lung Cancer | 45 | 1 |
| Apr 17, 2016: Ignyta Announces Updated Data from Entrectinib Phase 1 Clinical Trials at the 2016 AACR Annual Meeting | 46 | 2 |
| Apr 07, 2016: Ignyta Announces Oral Plenary Presentation and Poster Presentations at the 2016 AACR Annual Meeting | 48 | 1 |
| Mar 11, 2016: XALKORI (crizotinib) Approved by U.S. FDA for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer | 49 | 1 |
| Jan 06, 2016: New drug may overcome treatment resistance in a high-risk children cancer | 50 | 1 |
| Dec 09, 2015: Ignyta Announces Initiation of STARTRK "Next Generation" Phase 1/1b Pediatric Clinical Trial of Entrectinib | 51 | 1 |
| Dec 08, 2015: Pfizer Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for XALKORI (crizotinib) for the Treatment of Patients with ROS1-Positive Metastatic Non-Small Cell Lung Cancer | 52 | 1 |
| Dec 08, 2015: Ignyta Receives Orphan Drug Designation in the European Union for Entrectinib for the Treatment of Neuroblastoma | 53 | 1 |
| Nov 30, 2015: Ignyta and EORTC Announce Entrectinib Selected as First Investigational Cancer Agent to be Included in EORTC SPECTA Precision Medicine Clinical Trial Program | 53 | 1 |
| Nov 25, 2015: Pfizer Receives European Approval to Expand Use of XALKORI (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer | 54 | 1 |
| Nov 18, 2015: Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer | 54 | 1 |
| Sep 30, 2015: Ignyta Announces Initiation of STARTRK-2 Phase 2 Clinical Trial of Entrectinib | 55 | 3 |
| Appendix | 58 | 2 |
| Methodology | 58 | 1 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 58 | 1 |
| Expert Panel Validation | 58 | 1 |
| Contact Us | 58 | 1 |
| Disclaimer | 59 | 1 |
